en
Scientific article
Open access
English

Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug

Published inChemMedChem, vol. 13, no. 12, p. 1210-1217
Publication date2018
Abstract

The cytotoxicity of cisplatin (cDDP) is enhanced when co-administered with ethacrynic acid (EA), a glutathione S-transferase (GST) inhibitor. A Pt(IV)-EA conjugate containing a cDDP core and two axial ethacrynate ligands (compound 1) was shown to be an excellent inhibitor of GST, but did not readily release a Pt(II) species to exert a synergistic cytotoxic effect. Here, a redesigned Pt(IV) construct comprising of a cDDP core with one axial ethacrynate ligand and one axial hydroxo ligand (compound 2) was prepared and shown to overcome the limitations of 1. The EA ligand in 2 is readily released in vitro together with a cytotoxic Pt(II) species derived from cisplatin, working together to inhibit cell proliferation in cDDP-resistant human ovarian cancer cells. The in vitro activity translates well in vivo with 2 showing effective (ca. 80%) inhibition of tumor growth in a human ovarian carcinoma A2780 tumor model, while showing considerably lower toxicity than cisplatin, thus validating the new design strategy.

Keywords
  • Cancer
  • Cytotoxicity
  • Medicin al chemistry
  • Platinum
  • Redox chemistry
Citation (ISO format)
LEE, Keefe Guang Zhi et al. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug. In: ChemMedChem, 2018, vol. 13, n° 12, p. 1210–1217. doi: 10.1002/cmdc.201800105
Main files (2)
Article (Published version)
accessLevelRestricted
Article (Accepted version)
accessLevelPublic
Identifiers
ISSN of the journal1860-7179
294views
108downloads

Technical informations

Creation06/18/2020 11:36:00 AM
First validation06/18/2020 11:36:00 AM
Update time03/15/2023 10:09:26 PM
Status update03/15/2023 10:09:25 PM
Last indexation01/17/2024 10:10:00 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack